Dry Pharmaceutical Formulation for Stable Multi-Drug Delivery

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current pharmaceutical formulations, particularly aqueous solutions and suspensions, face issues such as degradation, unpalatability, particle agglomeration, stratification, and caking, which limit their suitability for administration, especially in young children and restrict patient compliance, and have a short shelf life.

Innovation Solution

Development of a dry formulation comprising antibiotics, anti-inflammatory steroids, and antifungal agents combined with pharmaceutically acceptable excipients, which can be administered as a capsule and reconstituted at the time of use, minimizing taste issues and maintaining potency, and is stable for 180 days.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If aqueous solutions or suspensions are used for drug delivery, then the drug can be administered easily, but the formulation has short shelf life due to degradation, particle agglomeration, stratification, and caking

Engineering Contradiction:
Improveease of administrationVSAvoidshelf life stability
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The patent transforms the formulation from liquid (aqueous solution/suspension) to solid (dry powder) state, fundamentally changing the physical parameter of the carrier. This parameter change eliminates water-related degradation pathways, particle agglomeration, stratification, and caking issues inherent in liquid formulations, thereby extending shelf life while maintaining ease of administration through reconstitution at the time of use

Inventive Principle:
Principle #35Parameter changes

2Productivity

If unpalatable drugs are carried in aqueous media for oral administration, then the drug can be delivered systemically, but the patient experiences unpleasant taste immediately upon ingestion

Engineering Contradiction:
Improvesystemic delivery effectivenessVSAvoidunpleasant taste
Core Design Contradiction:
ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent separates the drug substance from the oral cavity environment by using a dry powder carrier that is mixed with a flavored liquid immediately before administration. This segmentation allows the unpalatable drug to be delivered systemically without direct contact with taste receptors, as the drug is suspended in a small volume of flavored liquid that masks the unpleasant taste

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent introduces a flavored liquid carrier as an intermediary between the unpalatable drug and the patient's taste receptors. This intermediary medium (flavored liquid) masks the unpleasant taste of drugs like clarithromycin and erythromycin, allowing systemic delivery to proceed without the harmful effect of unpleasant taste

Inventive Principle:
Principle #24Intermediary (Mediator)

3Speed

If solution or suspension formulations are prepared in advance, then they are ready for immediate administration, but any unused portion must be discarded after minutes, leading to wasted medication

Engineering Contradiction:
Improvereadiness for administrationVSAvoidmedication waste
Core Design Contradiction:
SpeedVSLoss of substance

Solution Approach 1:

The patent performs preliminary preparation of the dry powder formulation in advance with extended stability, then completes the formulation reconstitution at the time of use. This allows the stable dry powder to be stored ready for administration, while the actual liquid formulation is prepared immediately before use, eliminating medication waste from discarded unused portions

Inventive Principle:
Principle #10Preliminary action

Data Source

PatentUS9925141B2Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders
Publication Date: 2018.03.27 CMPD LICENSING LLC

AI summary

In one aspect, a dry formulation for the effective administration of multiple medications simultaneously for one or more ailments may be provided. The dry formulations include one or more of the following actives in combination with pharmaceutically acceptable excipients or additives: a) at least one antibiotic; b) at least one anti-inflammatory steroid; and c) at least one antifungal agent.